



30<sup>th</sup> September 2009

**ANGEL BIOTECHNOLOGY HOLDINGS PLC  
("Angel" or "the Company")**

**Angel Biotechnology plc and Azellon Ltd / University of Bristol Sign GMP Manufacturing Contract**

**Angel Biotechnology Holdings plc, (AIM: ABH)** the biopharmaceutical contract manufacturer, is pleased to announce the signing of an agreement with Azellon and the University of Bristol. Under this agreement, Angel will provide development and GMP manufacturing services for Azellon's Phase I studies of its autologous cell therapy for meniscal repair. Financial details of the agreement were not disclosed.

Gordon Sherriff, COO of Angel Biotechnology plc said "We are delighted to have been awarded this contract by Azellon. Cell therapies promise to address many unmet medical needs across many disease categories and with our expertise and proven track record; Angel is well placed to meet the highest standards required by Azellon's therapeutic stem cell programme. Azellon, as a new customer for Angel, complements our growing client base and highlights our ability to support a diverse range of cell therapy projects. We look forward to working with Azellon on this exciting application."

Commenting on the contract, Troels Jordansen, Managing Director said "For any start-up company, capital investments in development and production laboratories are significant so outsourcing becomes an obvious alternative. After a thorough market analysis we are pleased to appoint Angel as our development and GMP production partner. Angel's in-house experience and facilities are second to none in the UK and we have great expectations".

**For further information, please call:**

**Angel Biotechnology Holdings plc**  
Gordon Sherriff – COO  
**Grant Thornton UK LLP**  
Philip Secrett, Colin Aaronson

Tel: +44 (0) 131 445 6077  
Tel: +44 (0) 7951 057016  
Tel+44 (0) 20 7383 5100

**About Angel Biotechnology Holdings plc**

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. Angel specializes in the provision of advanced biologics; these include autologous and allogeneic cell therapy products, stem cells, cellular vaccines, specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at [www.angelbio.com](http://www.angelbio.com).

## **Azellon**

Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model. [www.azellon-ltd.com](http://www.azellon-ltd.com).

## **About the University of Bristol**

The University of Bristol is committed to combining its excellence in research and innovation with a vibrant enterprise culture. The University is working with government, industry and other partner organisations to encourage the growth of knowledge based businesses in the South West. In particular, Bristol has joined forces with the Universities of Bath, Southampton and Surrey to establish the SETsquared Partnership to encourage enterprise, build new businesses and work more effectively with industry. As research-intensive universities, these enterprise activities derive from their research base, although support is also available to entrepreneurs from outside the universities. With a combined research staff of 6,400 and research budget of £266 million, the resulting contribution to the UK 'knowledge economy' is far greater than could be achieved individually. The partnership offers:

- Enterprise training and education
- Support for new businesses from within and external to the universities
- Access to innovative research that could lead to new products and processes

[www.bristol.ac.uk/research](http://www.bristol.ac.uk/research)